Myriad Showcases Its Pioneering Research at the 2015 ASCO

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Myriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting

SALT LAKE CITY, May 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN ) today announced it will present data from 19 clinical studies at the 2015 American Society of Clinical Oncology annual meeting to be held May 29 to June 2, 2015 in Chicago, Ill. Key podium presentations will highlight new prospective research programs with advanced companion diagnostic and molecular diagnostic tests aimed at revolutionizing how we treat and prevent cancers. Abstracts of the Company's presentations are available at: abstracts.asco.org .

"Advances in personalized medicine will include selecting effective pharmaceuticals (companion diagnostics), preventing disease (hereditary caner tests) and in optimizing treatment decisions (prognostic tests). This meeting showcases our pioneering research in these three areas of personalized medicine. In companion diagnostics, the myChoice™ HRD test can transform the way we personalize treatment plans for ovarian and breast cancers today and many other cancers in the future," said Mark Capone, president Myriad Genetic Laboratories. "Another critical goal for personalized medicine is to prevent cancer. Our myRisk™ hereditary cancer panel test does just that by analyzing 25 genes associated with eight common hereditary cancers. Lastly, our prognostic tests demonstrate advances in optimizing treatments decisions in prostate cancer and lung cancer. As a pioneer in the field of personalized medicine, we remain firmly committed to scientific progress through outstanding research that can ultimately benefit patients."

The list of key Myriad presentations follows.

1.  COMPANION DIAGNOSTIC PRESENTATIONS
myChoice HRD™: Podium Presentation
Title: Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto.
Presenter: Gunter Von Minckwitz
Date: Monday, June 1, 4:12 – 4:24 p.m.
Location N Hall B1; Abstract: 1004
   
myChoice HRD: Poster Discussion Sessions
Title: Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579).
Presenter: Virginia Kaklamani
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: N Hall B1; Abstract: 1017, Poster: 131
   
Title: Combined homologous recombination deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple negative and/or BRCA1 /2 mutation associated breast cancer.
Presenter: Melinda Telli
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: N Hall B1; Abstract: 1018, Poster: 132
   
myChoice HRD: Poster Sessions
Title: Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.
Presenter: Kirsten Timms
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: Abstract: 1091, Poster: 205
   
Title: Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance.
Presenter: Anosheh Afghahi
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: Abstract: 1094, Poster: 208
   
Title: Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC).
Presenter: Jai Patel
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: 5534, Poster: 92
   
Title: Use of homologous recombination deficiency (HRD) score to enriche for niraparib sensitive high grade ovarian tumors.
Presenter: Keith Wilcoxen
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: 5532, Poster: 90
   
Title: Homologous recombination (HR) deficiency, tumor BRCA 1/2 mutations (tm BRCA ) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC).
Presenter: Robert Brown
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: 5576, Poster: 134
   
BRACAnalysis CDx™: Poster Session
   
Title: A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.
Presenter: Stephanie Lheureux
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: TPS5613, Poster: 167a
   
2.  HEREDITARY CANCER PRESENTATIONS
myRisk™ Hereditary Cancer: Podium Presentation
Title: Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed <age 50.
Presenter: Judy Garber
Date: Saturday, May 30, 2:15 to 2:27 p.m.
Location: S 100BC; Abstract: 1503
   
myRisk Hereditary Cancer: Poster Discussion Sessions
Title: Outcomes of clinical testing for 50,000 patients utilizing a panel of 25 genes associated with increased risk for breast, ovarian, colorectal, endometrial, gastric, pancreatic, melanoma and prostate cancers.
Presenter: Eric Rosenthal
Date: Monday, June 1, 1:15 to 4:45 p.m.
Location: S102, Abstract: 1515, Poster: 338
   
Title: Assessment of the clinical presentation for patients discovered to have at least two deleterious mutations on multigene panel testing.
Presenter: Jeff Weitzel
Date: Monday, June 1, 1:15 to 4:45 p.m.
Location: S102, Abstract: 1514, Poster: 337
   
myRisk Hereditary Cancer: Poster Session
   
Title: A study of triple-negative breast cancer patients tested with a 25-gene panel of hereditary cancer genes.
Presenter: John Sandbach
Date: Saturday, May 30, 8:00 to 11:30 a.m.
Location: Abstract: 1067, Poster: 181
   
Title: Multi-gene panel testing in an unselected endometrial cancer cohort.
Presenter: Kari Ring
Date: Monday, June 1, 1:15 to 4:45 p.m.
Location: Abstract: 1533, Poster: 357
   
3.  PROGNOSTIC TEST PRESENTATIONS
   
myPlan® Lung Cancer: Poster Session
   
Title: Validation of a cell cycle progression score for 5-year mortality risk in patients with stage I non-small cell lung cancer.
Presenter: Takashi Eguchi
Date: Monday, June 1, 8:00 to 11:30 a.m.
Location: Abstract: 7522, Poster: 269
   
Prolaris®: Poster Session
   
Title: Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing.
Presenter: John Davis
Date: Saturday, May 30, 1:15 to 4:45 p.m.
Location: Abstract: 5033, Poster: 25
   
Prolaris: Abstract Publications
   
Title: Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.
Author: Jack Cuzick. Abstract: e16040
   
Title: Impact of CCP test on personalizing treatment decisions: results from a prospective registry of newly diagnosed prostate cancer patients.
Author: Neal Shore. Abstract: e16042
   
Title: Evaluation of the economic impact of the CCP assay in localized prostate cancer.
Author: David Crawford. Abstract: e16037

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad is focused on strategic initiatives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, and expand internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Myriad, the Myriad logo, BART, BRAC Analysis , Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, MyChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of new clinical data on myChoice HRD, myRisk Herditary Cancer, BRACAnalysis CDx, Prolaris and myPlan Lung Cancer at the ASCO 2015 meeting; the ability of our new companion diagnostic tests, such as myChoice™ HRD, to transform the way we personalize treatment plans for ovarian and breast cancers today and many other cancers in the future; the ability of our myRisk™ hereditary cancer panel test to help prevent cancer ; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing to new testing services, including unexpected costs and delays; risks related to decisions or changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of in our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 569

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 101

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 94

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 81

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 42

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 17

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 103

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
tion End -->

Top 5 Most Recently Viewed Articles

Investors Eye Holiday Spending Surge with Retail ETFs

Updated Category News Views 230

Holiday Spending Trends Point to Retail ETF Gains As the festive season kicks off, investors are buzzing with anticipation. The projections indicate a remarkable surge in U.S. holiday sales, expected to hit between $1.01 trillion and $1.02 trillion. This optimism is driven by strong consumer demand, early sales promotions, and a decrease in inflation, setting a promising...

Continue Reading
Titan Mining Announces Details for Upcoming AGM Meeting

Updated Category News Views 263

Titan Mining Corporation's Upcoming Annual General Meeting Titan Mining Corporation (TSX: TI; OTCQB: TIMCF) is set to hold its annual general meeting soon, a much-anticipated event for shareholders and stakeholders alike. The date is indeed significant as it marks an opportunity for the company to engage directly with its investors. Meeting Details and Importance The...

Continue Reading
She Said Yes Launches Eco-Friendly Jewelry Initiative

Updated Category News Views 219

She Said Yes Empowers Customers with Tree-Planting Initiative She Said Yes, a renowned jewelry brand dedicated to using conflict-free diamonds and recycled gold, has unveiled an exciting partnership with WeForest to create a meaningful environmental initiative. This new program enables every jewelry purchase to contribute directly to global reforestation efforts,...

Continue Reading
Whale Traders Target Trump Media's Future with Options Movements

Updated Category News Views 121

Whale Traders Target Trump Media's Future with Options Movements Recently, investors with substantial capital have been showing strong interest in Trump Media & Technology (NASDAQ: DJT). This surge in activity is a signal that retail traders should pay attention to. Today, unusual trading patterns have been detected, hinting that significant financial players are...

Continue Reading
Partnership Boosts Digital Transformation in Japan's Life Sciences

Updated Category News Views 153

Transforming the Life Sciences Industry through Digital Solutions ValGenesis Inc. has teamed up with Hitachi Industry & Control Solutions, Ltd. to spearhead a transformative initiative aimed at elevating the capabilities of life sciences companies in Japan. This innovative partnership intends to bring forth cutting-edge digital validation solutions to streamline processes...

Continue Reading